Vomacur 40 mg 5 suppositories
Vomacur is a product belonging to the group of H1- antihistamines applied against nausea and vomiting.
Vomacur medicine to prevent and treat motion sickness, dizziness, nausea and vomiting.
Dimenhydrinate alone is not suitable for the treatment of nausea and vomiting in chemotherapy (treatment of cancer).
2. What you should know before using Vomacur
Do not use Vomacur:
if you are allergic to dimenhydrinate to other antihistamines or any of the other ingredients of this medicine (listed in section 6);
acute asthma attack;
glaucoma (narrow-angle glaucoma);
at Adrenal tumor (pheochromocytoma);
in impaired formation of hemoglobin (porphyria);
an increase of the prostate (prostatic hypertrophy) with urinary retention;
in seizures (epilepsy, eclampsia).
Warnings and Precautions
Talk to your doctor before using Vomacur if you suffer from any of the following:
abnormal liver function;
cardiac arrhythmias (eg. increased heart rate);
deficiency of potassium or magnesium;
slow heartbeat (bradycardia);
certain heart diseases (congenital QT syndrome or other clinically relevant cardiac disorders, particularly disorders in perfusion of the coronary arteries, conduction abnormalities of the heart, arrhythmias);
concomitant use with drugs known to prolong the QT interval of the ECG or lead to low blood potassium (see. section "Using other medicines");
chronic breathing difficulties and asthma;
narrowing the outlet of the stomach (pyloric stenosis);
impaired renal function (Vomakur should not be used in severe renal impairment).
You can use Vomacur in these conditions only after consulting a doctor.
Other medicines and Vomacur
Please tell your doctor or pharmacist if you are taking or have recently taken any other medicines, including medicines obtained without a prescription.
Coadministration of Vomakur and other centrally acting agents (drugs affecting the psyche, hypnotics, tranquillizers (sedatives), analgesics and anesthetics) may lead to a mutually enhancing effects.
Co-administration of other anticholinergic Vomakur products can lead to unexpectedly enhance the anticholinergic effect (eg. Atropine, biperiden or any products used for depression / tricyclic antidepressants /).
Concomitant use of Vomakur with monoamine oxidase inhibitors (medicines used to treat depression) is the possible development of life-threatening intestinal paralysis, urinary retention or increased intraocular pressure. Further can be observed a drop in blood pressure and enhance distortions of the central nervous system and respiratory depression. Therefore Vomakur should not be administered concurrently with monoamine oxidase inhibitors.
You should avoid concomitant use with drugs:
may also prolong the QT interval of the ECG, eg. medicines used in arrhythmia (antiarrhythmic agents Class IA and III), certain antibiotics (eg. erythromycin), cisapride, antimalarials, medicines used for allergies or stomach / intestinal ulcers (antihistamines) or medicines used in specific psychiatric disorders (neuroleptics) ;
may give rise to potassium deficiency (eg. certain diuretics).
Applying Vomakur together with the products used in high blood pressure, can lead to increased fatigue and a greater decrease in blood pressure.
Your doctor should be notified of the application of Vomakur held before allergy testing since it is possible to get a false negative results.
Vomakur may mask the hearing damage caused by the use of certain antibiotics (aminoglycosides).
Vomakur with food and drink
Administration of Vomacur should avoid alcohol, as it can change and enhance the effect of Vomacur unpredictable. For this reason, the ability to drive and use machines is also impaired.
Pregnancy and lactation
If you are pregnant or breast-feeding, you think you may be pregnant or planning to become pregnant, talk to your doctor before taking this medicine.
Vomacur should not be applied in the last weeks of pregnancy because of the risk of prenatal contractions.
In the first six months of pregnancy Vomakur can be applied only if the previously applied non-drug measures have unsatisfactory result and the physician considers it imperative that treatment with the product.
There are no definite data on teratogenicity, reproductive toxicity and incidence of malformations with the use of dimenhydrinate during pregnancy.
Dimenhydrinate passes into breast milk. There is no experience with the use of dimenhydrinate during lactation. Administration should be discontinued or breastfeeding - stopped treatment with Vomakur as likely to experience side effects such as increased irritability in the infant.
Driving and using machines
Sleepiness, memory impairment and decreased concentration may impair ability to drive and / or operate machinery. This is especially true after insufficient sleep duration at baseline and change in the product as well as in combination with alcohol (see. Section "Use of Vomacur with food and drink").
3. How to use Vomakur
Always use this medicine exactly as your doctor has told you. If you're not sure, ask your doctor or pharmacist.
The dosage of dimenhydrinate should be guided by patient body weight. In young patients, and those with low weight lowest dose may be sufficient to reduce the symptoms in the respective age class patients.
Unless otherwise prescribed by Vomakur by your doctor, the dosage of 5 mg / kg body weight per day should not be exceeded.
If the doctor has otherwise prescribed, the recommended dose is:
Small children weighing 8-15 kg:
Vomakur 1 suppository once daily.
Children weighing 15-25 kg:
1 suppository Vomakur 2 times daily.
Children weighing more than 25 kg:
1 suppository Vomakur 2-3 times daily.
In addition, please keep the following maximum dose:
Children aged 6 to 14 years - 150 mg of dimenhydrinate day.
For prevention of motion sickness first dose given on average 1/2 to 1 hour before traveling. For the treatment of nausea and vomiting are divided doses at regular intervals throughout the day.
Suppositories are placed deep in the rectum.
Duration of use
Vomakur is intended for short course of treatment, unless otherwise prescribed by the doctor. At constant malaise we must be consulted with a doctor to determine further treatment. The need for treatment Vomakur must be checked no later than two weeks of treatment.
Please ask your doctor if you feel that the effect of Vomakur is too strong or too weak.
If you use more than the amount Vomacur
Dimenhydrinate intoxication can be life-threatening. Children are under particularly high risk.
In case of overdose or intoxication Vomakur should seek immediate consultation with a doctor (emergency).
Vomakur overdose is characterized depending on the dose, with different stages of reduced consciousness - a strong drowsiness to unconsciousness. There were also signs of "anticholinergic syndrome": dilated pupils, visual disturbances, increased heart rate, fever, hot and red skin, dry mucous membranes, constipation, anxiety, fear, anxiety, overactive reflexes, hallucinations. Also, when high doses are possible attacks and disordered breathing, which may lead to paralysis of the respiratory system and heart block after high doses.
The doctor assess the severity of the poisoning and the need to implement appropriate measures.
If you forget to use Vomacur
Do not take a double dose to make up and continue the application as prescribed by your doctor.
If you stop using Vomakur
Please do not interrupt or stop the application of Vomakur without consulting your doctor.
If you have any further questions on the use of this product, ask your doctor or pharmacist.
4. Possible side effects
Like all medicines, Vomacur can cause side effects, although not everybody gets them.
Assessment of the incidence of adverse reactions is based on the following categories:
Very common: more than 1 in 10 treated patients;
Common: less than 1 in 10 but more than 1 in 100 patients treated;
Uncommon: less than 1 in 100 but more than 1 in 1000 patients treated;
Rare: less than 1 in 1,000, but more than 1 in 10 000 patients treated;
Very rare: less than 1 in 10,000, incl. individual cases;
Not known: can not be estimated from the available data.
Clinically significant adverse reactions or symptoms that you should know if you are affected:
If you hit some of these side effects, do not apply Vomakur again, consult your doctor immediately if possible.
Depending on individual sensitivity and the dose often occur following adverse reactions, especially at the beginning of therapy: drowsiness, dizziness and muscle weakness. These reactions can lead to disorders even the next day.
It can often be seen called. "anticholinergic syndrome" that is associated with dry mouth, increased heart rate (tachycardia), feeling stuffy nose, visual disturbances, increased intraocular pressure and abnormal urination. There have gastrointestinal discomfort (eg. Nausea, pain in the stomach, vomiting, constipation or diarrhea), and mood changes. Especially in children may occur "paradoxical reactions" such as anxiety, agitation, insomnia, fear or trembling.
Furthermore, there is evidence of allergic skin reactions and photo sensitivity of the skin (avoid direct exposure to the sun) and liver function abnormalities (cholestatic jaundice).
In some cases it may be a violation of the blood picture.
With prolonged treatment and abrupt discontinuation it is likely to experience insomnia. In the long term use can not be excluded according to Your doctor will determine the duration of treatment.
Other possible side effects
After prolonged administration of dimenhydrinate can not be excluded development of dependency. Therefore Vomakur should be used for a short period, if possible.
After prolonged use after abrupt discontinuation of treatment may be a temporary sleep disorder. For this reason, treatment should be discontinued.
6. Contents of the pack and further information
What Vomacur 40 mg suppositories
The active substance is dimenhydrinate. Each suppository contains 40 mg of dimenhydrinate.
The other ingredients are: solid mass.
Vomacur looks like and contents of the pack
Suppositories - white with torpadeo form.
Original packs of 5 and 10 suppositories.
Not all pack sizes may be marketed.